$QUBT
Quantum Computing Inc. Stock $qubt

$qubt Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-K Financial Statement

#000121390025025561 Filed on March 20, 2025

Income Statement

Concept	2025 Q1	2024 Q4	2024
Revenue			$373.0K
YoY Change			4.18%
Cost Of Revenue			$261.0K
YoY Change			33.41%
Gross Profit			$112.0K
YoY Change			-31.04%
Gross Profit Margin			30.03%
Selling, General & Admin			$14.73M
YoY Change			-29.64%
% of Gross Profit			13152.68%
Research & Development			$11.32M
YoY Change			75.54%
% of Gross Profit			10105.36%
Depreciation & Amortization			$694.0K
YoY Change			-64.55%
% of Gross Profit			619.64%
Operating Expenses			$26.05M
YoY Change			-4.87%
Operating Profit			-$25.94M
YoY Change			-4.72%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income			-$68.54M
YoY Change			130.54%
Income Tax
% Of Pretax Income
Net Earnings			-$68.54M
YoY Change			130.54%
Net Earnings / Revenue			-18375.87%
Basic Earnings Per Share			-$0.73
Diluted Earnings Per Share			-$0.73
COMMON SHARES
Basic Shares Outstanding	137.2M shares	91.35M shares	93.88M shares
Diluted Shares Outstanding			93.88M shares

Balance Sheet

Concept	2025 Q1	2024 Q4	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$78.90M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory		$18.00K
Prepaid Expenses
Receivables		$27.00K
Other Receivables
Total Short-Term Assets		$79.15M
YoY Change		2387.66%
LONG-TERM ASSETS
Property, Plant & Equipment		$8.212M
YoY Change		123.78%
Goodwill		$55.57M
YoY Change		-7.93%
Intangibles		$8.972M
YoY Change		-21.22%
Long-Term Investments
YoY Change
Other Assets		$129.0K
YoY Change		-0.04%
Total Long-Term Assets		$74.41M
YoY Change		-1.51%
TOTAL ASSETS
Total Short-Term Assets		$79.15M
Total Long-Term Assets		$74.41M
Total Assets		$153.6M
YoY Change		95.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.372M
YoY Change		-6.13%
Accrued Expenses		$2.134M
YoY Change		989.22%
Deferred Revenue		$79.00K
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$4.559M
YoY Change		-1.31%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$4.559M
Total Long-Term Liabilities
Total Liabilities		$46.27M
YoY Change		747.52%
SHAREHOLDERS EQUITY
Retained Earnings		-$200.5M
YoY Change		33.92%
Common Stock		$13.00K
YoY Change		67.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$107.3M
YoY Change
Total Liabilities & Shareholders Equity		$153.6M
YoY Change		95.05%

Cashflow Statement

Concept	2025 Q1	2024 Q4	2024
OPERATING ACTIVITIES
Net Income			-$68.54M
YoY Change			130.54%
Depreciation, Depletion And Amortization			$694.0K
YoY Change			-64.55%
Cash From Operating Activities			-$16.21M
YoY Change			-18.69%
INVESTING ACTIVITIES
Capital Expenditures			$6.036M
YoY Change			184.99%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			-$6.036M
YoY Change			130.56%
FINANCING ACTIVITIES
Cash Dividend Paid			$215.0K
YoY Change			-75.14%
Common Stock Issuance & Retirement, Net			$106.8M
YoY Change			318.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$99.14M
YoY Change			413.4%
NET CHANGE
Cash From Operating Activities			-$16.21M
Cash From Investing Activities			-$6.036M
Cash From Financing Activities			$99.14M
Net Change In Cash			$76.89M
YoY Change			-2466.32%
FREE CASH FLOW
Cash From Operating Activities			-$16.21M
Capital Expenditures			$6.036M
Free Cash Flow			-$22.25M
YoY Change			0.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-12-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-40615
CY2024	dei	Entity Registrant Name EntityRegistrantName	QUANTUM COMPUTING INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-4533053
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Marine View Plaza
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 214
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Hoboken
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07030
CY2024	dei	City Area Code CityAreaCode	(703)
CY2024	dei	Local Phone Number LocalPhoneNumber	436-2121
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $.0001
CY2024	dei	Trading Symbol TradingSymbol	QUBT
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Public Float EntityPublicFloat	34743396	usd
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	137244545	shares
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag	true
CY2024	cyd	Cybersecurity Risk Third Party Oversight And Identification Processes Flag CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag	false
CY2024	cyd	Cybersecurity Risk Management Third Party Engaged Flag CybersecurityRiskManagementThirdPartyEngagedFlag	true
CY2024	cyd	Cybersecurity Risk Materially Affected Or Reasonably Likely To Materially Affect Registrant Flag CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag	true
CY2024Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q4	qubt	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false
CY2024Q4	qubt	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
CY2024Q4	ecd	Insider Trd Policies Proc Adopted Flag InsiderTrdPoliciesProcAdoptedFlag	false
CY2024	dei	Auditor Firm AuditorFirmId	207
CY2024	dei	Auditor Name AuditorName	BPM LLP
CY2024	dei	Auditor Location AuditorLocation	San Jose, California
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78945000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2059000	usd
CY2024Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	65000	usd
CY2024Q4	us-gaap	Inventory Net InventoryNet	18000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	73000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	279000	usd
CY2024Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	161000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	180000	usd
CY2024Q4	us-gaap	Assets Current AssetsCurrent	79151000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2656000	usd
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8212000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2870000	usd
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1522000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1051000	usd
CY2024Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8972000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12076000	usd
CY2024Q4	us-gaap	Goodwill Goodwill	55573000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	55573000	usd
CY2024Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	129000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	129000	usd
CY2024Q4	us-gaap	Assets Assets	153559000	usd
CY2023Q4	us-gaap	Assets Assets	74355000	usd
CY2024Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1372000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1462000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2134000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	639000	usd
CY2023Q4	us-gaap	Financial Services Liabilities FinancialServicesLiabilities	1925000	usd
CY2024Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	79000	usd
CY2024Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	974000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	786000	usd
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4559000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4812000	usd
CY2024Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	40532000	usd
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1181000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	840000	usd
CY2024Q4	us-gaap	Liabilities Liabilities	46272000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5652000	usd
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	129012000	shares
CY2024Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	129012000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77451000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77451000	shares
CY2024Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2024Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	307756000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200635000	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-200482000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131940000	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	107287000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	68703000	usd
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153559000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74355000	usd
CY2024	us-gaap	Revenues Revenues	373000	usd
CY2023	us-gaap	Revenues Revenues	358000	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	261000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	196000	usd
CY2024	us-gaap	Gross Profit GrossProfit	112000	usd
CY2023	us-gaap	Gross Profit GrossProfit	162000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11318000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8891000	usd
CY2024	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1818000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1806000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12913000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15708000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	26049000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	26405000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-25937000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-26243000	usd
CY2024	us-gaap	Interest And Other Income InterestAndOtherIncome	423000	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	295000	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2496000	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1602000	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	40532000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-528000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68542000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27022000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-68542000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27022000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	861000	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-68542000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27883000	usd
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93881000	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93881000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66611000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66611000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	65124000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	24730000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1000	usd
CY2023	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	861000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4238000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2493000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27022000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	68703000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	106766000	usd
CY2024	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4097000	usd
CY2024	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-8195000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4322000	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	136000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-68542000	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	107287000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-68542000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27022000	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3798000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3307000	usd
CY2024	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2059000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	925000	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	40532000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-528000	usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	666000	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	279000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	279000	usd
CY2024	qubt	Other Recognized Lossesgains OtherRecognizedLossesgains	-4000	usd
CY2023	qubt	Other Recognized Lossesgains OtherRecognizedLossesgains	-5000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	5782000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4271000	usd
CY2024	qubt	Stockbased Compensation Expense For Services StockbasedCompensationExpenseForServices	23000	usd
CY2023	qubt	Stockbased Compensation Expense For Services StockbasedCompensationExpenseForServices	284000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-38000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	52000	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-55000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	70000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-16000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	110000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	69000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-90000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	596000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	79000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	550000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	110000	usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-130000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-241000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16213000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18315000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6036000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2112000	usd
CY2023	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	500000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6036000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2612000	usd
CY2024	qubt	Proceeds Raised From Financial Liabilities Net Of Issuance Costs ProceedsRaisedFromFinancialLiabilitiesNetOfIssuanceCosts	6995000	usd
CY2024	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	10313000	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	6187000	usd
CY2024	us-gaap	Payments Of Dividends PaymentsOfDividends	215000	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	865000	usd
CY2024	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	4098000	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	106766000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24730000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	99135000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17678000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	76886000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3249000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2059000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5308000	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78945000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2059000	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	268000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	813000	usd
CY2024	qubt	Reclassification Of Series A Preferred Stock To Mezzanine Equity ReclassificationOfSeriesAPreferredStockToMezzanineEquity	8195000	usd
CY2024	qubt	Valuation Of Derivative Associated With Convertible Financial Liability ValuationOfDerivativeAssociatedWithConvertibleFinancialLiability	666000	usd
CY2024	qubt	Conversion Of Series A Preferred To Common Stock ConversionOfSeriesAPreferredToCommonStock	4097000	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	765000	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – Nature of the Organization and Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Corporate History</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantum Computing Inc. (“QCi” or the “Company”) was formed in the State of Nevada on July 25, 2001, under its original name, Ticketcart, Inc., which was changed to Innovative Beverage Group Holdings, Inc. in 2009. The Company redomiciled to Delaware on February 22, 2018 and changed its name to Quantum Computing Inc. Effective July 20, 2018, the trading symbol for the Company’s common stock, par value $0.0001, on the OTC Market changed from “IBGH” to “QUBT”. On July 15, 2021 the Company uplisted to The Nasdaq Stock Market LLC. On June 16, 2022, the Company merged with QPhoton, Inc. (“QPhoton”), a developer of quantum photonic systems and related technologies and applications. The QPhoton Merger enabled us to develop hardware applications integrated with the Company’s software platform, Qatalyst, that existed before the QPhoton Merger.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Nature of Business</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">QCi is an American company utilizing integrated photonics and non-linear quantum optics to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging and cybersecurity applications based on patented and proprietary photonics technology. QCi’s products are designed to operate at room temperature and at very low power levels compared to other quantum systems currently available in the market, such as superconducting, ion-trap, or annealing architectures. Our core photonics technology enables the execution of a go-to-market strategy which emphasizes scalability, accessibility and affordability. Our quantum machines, supported by professional services through our “Quantum Solutions” offering, enable subject matter experts (SMEs) and end users to deliver critical business solutions involving highly complex optimization problems.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The leading application of our quantum offerings today is our Entropy Quantum Computing. Our longer-term product development plan is to migrate the EQC’s current design, as well as other product designs based on discrete components, to a set of optical integrated circuits (TFLN Optical Chips) built on TFLN wafers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidity</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, the realization of assets, and the satisfaction of liabilities in the normal course of business. We have not achieved a level of sales adequate to support the Company’s cost structure. The Company has historically incurred losses and negative cash flows from operations. During the year ended December 31, 2024, the Company issued 49,679 shares of common stock for net proceeds of $106.8 million. Cash and cash equivalents on hand were $78.9 million as of December 31, 2024. As of December 31, 2024, the Company also had an accumulated deficit of $200.5 million and working capital of $74.6 million. In January 2025, the Company issued 8,163,266 shares of common stock for net proceeds of $93.3 million. As a result, the Company has adequate cash and cash equivalents on hand to meet its obligations over the next 12 months.</p>
CY2024	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2018-07-20
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	106800000	usd
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78900000	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-200500000	usd
CY2024	qubt	Working Capital Deficit WorkingCapitalDeficit	74600000	usd
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Reclassifications</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to the fiscal year 2023 consolidated financial statements to conform ot the fiscal year 2024 presentation. The reclassifications had no impact on net loss, total assets, total liabilities, or stockholders’ equity.</p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of goodwill and intangible assets, deferred tax assets, equity-based transactions and liquidity assessment. Actual results may differ from these estimates.</p>
CY2024Q4	us-gaap	Deposits Money Market Deposits DepositsMoneyMarketDeposits	78900000	usd
CY2023Q4	us-gaap	Deposits Money Market Deposits DepositsMoneyMarketDeposits	960000	usd
CY2024	us-gaap	Revenues Revenues	373000	usd
CY2023	us-gaap	Revenues Revenues	358000	usd
CY2024Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.04	pure
CY2024	us-gaap	Revenues Revenues	373000	usd
CY2023	us-gaap	Revenues Revenues	358000	usd
CY2024	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	3500	usd
CY2024Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	78900000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	78900000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-68542000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27022000	usd
CY2023	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	861000	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-68542000	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-68542000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-27883000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27883000	usd
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93881000	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93881000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66611000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66611000	shares
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18487000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19525000	shares
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024	us-gaap	Interest And Other Income InterestAndOtherIncome	423000	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	295000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16991000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8019000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8972000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16991000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4915000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12076000	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3100000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3100000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2472000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2021000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1903000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1819000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	757000	usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8972000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.031	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.124	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.02	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.027	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.005	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.001	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.003	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.001	pure
CY2024	qubt	Effective Income Tax Rate Reconciliation True Ups Income Taxes EffectiveIncomeTaxRateReconciliationTrueUpsIncomeTaxes	0	pure
CY2023	qubt	Effective Income Tax Rate Reconciliation True Ups Income Taxes EffectiveIncomeTaxRateReconciliationTrueUpsIncomeTaxes	0	pure
CY2022	qubt	Effective Income Tax Rate Reconciliation True Ups Income Taxes EffectiveIncomeTaxRateReconciliationTrueUpsIncomeTaxes	0	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.06	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.223	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.237	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.004	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	89000000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	7000000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	0.80	pure
CY2024	us-gaap	Subsidiary Or Equity Method Investee Cumulative Percentage Ownership After All Transactions SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions	0.50	pure
CY2024Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	89400000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.30	pure
CY2024Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14000000	usd
CY2024Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	3000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.26	pure
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2000000	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	16000000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	878000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	96767000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	167774000	usd
CY2024Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	263541000	usd
CY2024Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9178000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3142000	usd
CY2024Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	966000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	272000	usd
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8212000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2870000	usd
CY2024	us-gaap	Property Plant And Equipment Gross Period Increase Decrease PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease	6000000	usd
CY2024	us-gaap	Depreciation Depreciation	694000	usd
CY2023	us-gaap	Depreciation Depreciation	203000	usd
CY2024	qubt	Property Plant And Equipment Yet To Placed Have Not Started Depreciating PropertyPlantAndEquipmentYetToPlacedHaveNotStartedDepreciating	5400000	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2063000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	138000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1925000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	14000	usd
CY2024Q3	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	450000	usd
CY2024Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	55000	usd
CY2022Q1	us-gaap	Investment Sold Not Yet Purchased Balance Principal Amount InvestmentSoldNotYetPurchasedBalancePrincipalAmount	1250000	usd
CY2022Q2	us-gaap	Investment Sold Not Yet Purchased Balance Principal Amount InvestmentSoldNotYetPurchasedBalancePrincipalAmount	1250000	usd
CY2022Q2	us-gaap	Loans Assumed1 LoansAssumed1	2500000	usd
CY2022Q2	us-gaap	Investment Interest Rate InvestmentInterestRate	0.15	pure
CY2022Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.15	pure
CY2024	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8 – Contingencies </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Indemnification Arrangements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We enter into standard indemnification arrangements in our ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties (generally our business partners or customers) in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to our products. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the estimated fair value of these agreements is minimal.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into indemnification agreements with our directors and officers that may require us to indemnify our directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of a culpable nature. These agreements also require us to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified and to make good faith determination whether or not it is practicable for us to obtain directors and officers insurance. We currently have directors and officers liability insurance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Legal Proceedings</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. In general, management believes that ordinary course of business matters will not have a material adverse effect on our consolidated financial position or consolidated results of operations and are adequately covered by our liability insurance. However, it is possible that consolidated cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one of more of these contingencies or because of the diversion of management’s attention and the incurrence of significant expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Part I, Item 3, <i>Legal Proceedings</i>, in this Form 10-K for additional details on the status of the following proceedings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">BV Advisory v. QCi Breach Lawsuit</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of the QPhoton Merger in June 2022, QPhoton had an outstanding balance of principal and interest due to BV Advisory based on a note purchase agreement that QPhoton had entered into with BV Advisory on March 1, 2021 (the “BV Note Purchase Agreement”). Accordingly, the Company has recorded an estimated payable (the “BV Advisory Payable”), recognized as other current liabilities on the consolidated financial statements, based on best available information in the amount of $536 thousand as of December 31, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2022, BV Advisory filed a complaint Delaware Chancery Court naming the Company and certain of its directors and officers (among others) as defendants seeking, among other relief, monetary damages for an alleged breach of the BV Note Purchase Agreement. During the year ended December 31, 2024, BV Advisory’s other claims were dismissed by the Delaware Chancery Court and BV Advisory transferred its claim for breach of the BV Note Purchase Agreement to the Delaware Superior Court. The Company believes that BV Advisory’s claims have no merit and intends to defend itself vigorously. BV Advisory’s claims are not covered by the Company’s liability insurance, nor does the Company believe it is necessary to accrue an amount in addition to the BV Advisory Payable at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">BV Advisory v. QCi Appraisal Action</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BV Advisory was purportedly a shareholder of QPhoton, Inc., the predecessor in interest to QPhoton, LLC, a wholly owned subsidiary of the Company (both referred to as “QPhoton” in this Legal Proceedings discussion). BV Advisory rejected the Merger Consideration (as defined below) and on October 13, 2022 filed a petition in the Delaware Chancery Court seeking appraisal of the shares of QPhoton it allegedly owned (which shares represented 10% of the shares of QPhoton outstanding immediately prior to the Company’s acquisition of QPhoton). The Appraisal Petition is currently pending in Delaware Chancery Court. The Company included BV Advisory’s purported ownership of QPhoton in the purchase price accounting for the QPhoton Merger.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s total purchase price of QPhoton was approximately $71.0 million, or $69.9 million net of cash acquired, consisting of Company common stock, Series B Preferred Stock and QPhoton Warrants (as defined below). While the total shares of the Company’s common stock on an as-converted basis offered in the QPhoton Merger was 36,600,823 (the “Merger Consideration”), the fair market valuation contemplated 31,299,417 of the shares, which assumed full conversion of the 2,377,028 shares of Series B Preferred Stock to common stock at the 10:1 ratio, and that only 1,726,931 of the warrants to purchase up to 7,028,337 shares of the Company’s common stock (the “QPhoton Warrants”) would eventually be exercised (specifically only the QPhoton Warrants for which the associated Company options and/or warrants had an exercise price at or below $2.27 at the time of the QPhoton Merger).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, as of December 31, 2024 and 2023, the Company has neither issued 2,957,251 shares of the Company’s common stock on an as converted basis (the “Unissued QPhoton Shares”) nor 702,834 warrants to purchase shares of the Company’s common stock (the “Unissued QPhoton Warrants”) that were included in the Merger Consideration. The Unissued QPhoton Shares are included in the statement of stockholder’s equity as additional paid in capital as of as of December 31, 2024 and 2023, and the Unissued QPhoton Warrants have a carrying value of $40.5 million as a liability on the Company’s consolidated balance sheet as of December 31, 2024, and <span style="-sec-ix-hidden: hidden-fact-96">no</span> carrying value as a liability on the Company’s consolidated balance sheet as of December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>QCi v. BV Advisory Injunction Lawsuit</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2025, the Company filed a complaint in Delaware Chancery Court against BV Defendants (BV Advisory and its principal Keith Barksdale) asserting claims for defamation, breach of contract, conversion, aiding and abetting conversion, and misappropriation of trade secrets based on the BV Defendants’ unauthorized possession and dissemination of certain of the Company’s confidential and privileged documents. The Company seeks, among other relief, injunctive relief and damages. On February 11, 2025, the Court granted the Company’s motion for temporary restraining order and instructed the parties to negotiate an expedited case schedule. On February 13, 2025, the Court entered a stipulated case schedule that set a trial for April 8 and 9, 2025 on the Company’s claims for conversion, aiding and abetting conversion, and misappropriation of trade secrets. The parties are currently engaged in discovery. The Company does not believe it is necessary to accrue a litigation reserve at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Securities Class Action Lawsuit</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 25, 2025, a class action lawsuit was filed against the Company and certain of its current and past officers in the New Jersey District Court, by a plaintiff seeking to represent a class of all persons who purchased the Company’s securities between March 30, 2020 and January 15, 2025, alleging violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose material information about the Company’s customers, contracts and business operations. To date, the New Jersey District Court has not certified a class or designated a lead plaintiff. The Company disputes the allegations in the complaint, intends to vigorously defend against the claims asserted, and does not believe it is necessary to accrue a litigation reserve at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Arbitration over Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2025, the Company entered into arbitrations with Former Consultants (two individuals) regarding forfeiture of stock options. The Company had issued stock options to the consultants in 2020 and 2021 and terminated the Former Consultants’ agreements in March 2024, at which time the Company informed the Former Consultants that any vested options had to be exercised within three months of the termination date, per the Company’s Equity and Incentive Plans. The Former Consultants did not exercise their vested options, and the options were duly forfeited. In December 2024, the Former Consultants claim that they still retain the right to exercise the options, which the Company has rejected. The Company believes these claims are without merit, intends to defend itself vigorously, and does not believe it is necessary to accrue a litigation reserve at this time.</p>
CY2024	qubt	Fair Market Valuation Contemplated Shares FairMarketValuationContemplatedShares	31299417	shares
CY2024	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	2377028	shares
CY2024Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7028337	shares
CY2024Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	40500000	usd
CY2024Q4	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	558000	usd
CY2024Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	558000	usd
CY2024Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	5.5
CY2024Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	5.5
CY2024Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16000000	shares
CY2024Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.5
CY2024Q4	qubt	Other Offering Expenses OtherOfferingExpenses	40000000	usd
CY2024Q4	us-gaap	Convertible Debt ConvertibleDebt	9300000	usd
CY2024Q4	qubt	Cash Fee Percentage CashFeePercentage	0.0725	pure
CY2024Q4	qubt	Percentage Of Securities Sold PercentageOfSecuritiesSold	0.05	pure
CY2024Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.875
CY2024Q4	qubt	Fee And Expenses FeeAndExpenses	100000	usd
CY2024Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1540000	shares
CY2024Q4	qubt	Placement Shares PlacementShares	8460000	shares
CY2024Q4	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	5
CY2024Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	42300000	usd
CY2024Q4	us-gaap	Investment Interest Rate Paid In Cash InvestmentInterestRatePaidInCash	0.07	pure
CY2024Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	500000	usd
CY2024Q4	qubt	Percentage Of Securities Sold Offerings PercentageOfSecuritiesSoldOfferings	0.05	pure
CY2024Q4	qubt	Fee And Expenses FeeAndExpenses	100000	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	6300000	shares
CY2022Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.0001
CY2024	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	6300000	usd
CY2024	us-gaap	Product Warranty Expense ProductWarrantyExpense	7000000	usd
CY2024	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	457926	shares
CY2024	qubt	Forfeited Percentage ForfeitedPercentage	0.65	pure
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	40500000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-528000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9165000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.51
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M12D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5340000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.38
CY2023	qubt	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	662000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.41
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13843000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M12D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	830000	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.92
CY2024	qubt	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P5Y
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1690000	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.14
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12983000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.34
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8803000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.21
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y4M24D
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9646000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.66
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y8M12D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12983000	shares
CY2024Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9646000	shares
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5782000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4271000	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1500000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	33000	usd
CY2024	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	23000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	284000	usd
CY2024	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	142000	shares
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1600000	shares
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	437000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	591000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	515000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	212000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1755000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	136000	usd
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1619000	usd
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	438000	usd
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1181000	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	385000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	411000	usd
CY2024Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2024Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2024	qubt	Consideration Agreement Description ConsiderationAgreementDescription	As consideration for the license and other rights granted under the agreement, QPhoton agreed to pay the following: (i) $35 thousand within 30 days of execution of the agreement, (ii) $28 thousand within 30 days of each annual anniversary of the effective date, (iii) equity in the Company equivalent to 9.0% of the membership units of the Company within 30 days of the execution of the agreement, and (iv) royalties of 3.5% of the Net Sales Price of each licensed product sold or licensed by the Company during the quarter then-ended, for which it also received payment, concurrent with the delivery of the relevant quarterly report.
CY2024Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent		usd
CY2024Q4	us-gaap	Financial Services Liabilities FinancialServicesLiabilities		usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2024Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
CY2024	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable		usd
CY2023	qubt	Proceeds Raised From Financial Liabilities Net Of Issuance Costs ProceedsRaisedFromFinancialLiabilitiesNetOfIssuanceCosts		usd
CY2023	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock		usd
CY2023	qubt	Reclassification Of Series A Preferred Stock To Mezzanine Equity ReclassificationOfSeriesAPreferredStockToMezzanineEquity		usd
CY2023	qubt	Valuation Of Derivative Associated With Convertible Financial Liability ValuationOfDerivativeAssociatedWithConvertibleFinancialLiability		usd
CY2024	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash		usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive		usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2024Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent		usd
CY2024Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense		usd
CY2024Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure		usd
CY2024Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent		usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2024Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y
CY2024Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001758009
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001213900-25-025561-index-headers.html	Edgar Link	pending
0001213900-25-025561-index.html	Edgar Link	pending
0001213900-25-025561.txt	Edgar Link	pending
0001213900-25-025561-xbrl.zip	Edgar Link	pending
ea0234742-10k_quantum.htm	Edgar Link	pending
ea023474201ex10-20_quantum.htm	Edgar Link	pending
ea023474201ex10-30_quantum.htm	Edgar Link	pending
ea023474201ex19-1_quantum.htm	Edgar Link	pending
ea023474201ex21-1_quantum.htm	Edgar Link	pending
ea023474201ex23-1_quantum.htm	Edgar Link	pending
ea023474201ex31-1_quantum.htm	Edgar Link	pending
ea023474201ex31-2_quantum.htm	Edgar Link	pending
ea023474201ex32-1_quantum.htm	Edgar Link	pending
ea023474201ex32-2_quantum.htm	Edgar Link	pending
ea023474201ex4-5_quantum.htm	Edgar Link	pending
ex10-20_001.jpg	Edgar Link	pending
ex10-30_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qubt-20241231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
qubt-20241231_cal.xml	Edgar Link	unprocessable
qubt-20241231_def.xml	Edgar Link	unprocessable
qubt-20241231_pre.xml	Edgar Link	unprocessable
qubt-20241231_lab.xml	Edgar Link	unprocessable
ea0234742-10k_quantum_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QUBT
Quantum Computing Inc. Stock $qubt

2025 Q1 Form 10-K Financial Statement

#000121390025025561 Filed on March 20, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QUBT Quantum Computing Inc. Stock $qubt

2025 Q1 Form 10-K Financial Statement

#000121390025025561 Filed on March 20, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QUBT
Quantum Computing Inc. Stock $qubt